HIV/AIDS Editors' Choice: Top Stories of 2013

Letter to Readers |
December 30, 2013

HIV/AIDS Editors' Choice: Top Stories of 2013

  1. Paul E. Sax, MD

A perspective on the most important research in the field from the past year

  1. Paul E. Sax, MD

This has been an exciting year for us, with organizational changes that are reflected in our new title: NEJM Journal Watch AIDS Clinical Care. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do that better than ever.

The biggest change in HIV treatment over the past year has been the continued emergence of integrase inhibitor–based regimens as top options for first-line therapy. This trend began with raltegravir in the late 2000s, accelerated when co-formulated tenofovir/FTC/elvitegravir/cobicistat was approved in 2012, and now has been further strengthened by the recent approval of dolutegravir. In response to accumulating research and clinical data on tenofovir/FTC/elvitegravir/cobicistat and impressive results in the phase III dolutegravir studies, the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents recently issued an interim update to its “What to Start” section, which now includes both elvitegravir/cobicistat- and dolutegravir-based regimens as “preferred” options. On the prevention front, yet another candidate vaccine failed to demonstrate protective efficacy; better news emerged from a modeling analysis of HPTN 052 data, showing that early treatment of the HIV-infected partners in serodiscordant couples would at the very least be cost-effective, and may even be cost-saving. And finally, a long-awaited update to the occupational postexposure prophylaxis guidelines was released, offering clinicians a much more contemporary range of options for preventive therapy.

Our HIV/AIDS top stories of 2013 are:


Updated Recommendations on INSTI-Based Regimens for ART-Naive Patients

Occupational Postexposure Prophylaxis Guidelines, Updated

Antiretroviral PrEP for Injection-Drug Users?

Comparative Trial of Maraviroc vs. Tenofovir/FTC Halted

Early Treatment of Serodiscordant Couples Is Cost-Effective

Disappointing Results from Another HIV Vaccine Efficacy Trial

Presenting CD4-Cell Count Is Rising, but Slowly

Validating WHO-Recommended Second-Line ART

ART-Free Remission in an HIV-Infected Infant with Very Early Treatment

Editor Disclosures at Time of Publication

  • Disclosures for Paul E. Sax, MD at time of publication Consultant / Advisory board Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Janssen; Merck Grant / research support NIH; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck Editorial boards Medscape; UpToDate Leadership positions in professional societies Mass ID Society (Vice President)

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.